Clinical trials: First Progression of Glioblastoma
Astrocytoma, Glioblastoma
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for…
- Conditions
- Astrocytoma, Glioblastoma, Progressive Disease
- Trial name
- NCT07560865
- Testing
- FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Glioblastoma
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.
- Trial name
- NCT01259869
- Testing
- PX-866
- Where
- 7 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Glioblastoma
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
This multicenter, double-blind, placebo-controlled, randomized study will evaluate the efficacy and safety of the addition of bevacizumab treatment to lomustine (in 2nd-line [2L] treatment) and SOC (in 3rd-line [3L] and…
- Trial name
- NCT01860638
- Testing
- Bevacizumab, Lomustine, Radiotherapy
- Where
- 64 sites in Austria, Bulgaria and 13 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma (GBM)
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Approximately 58-68 total subjects will be enrolled. In the first stage, 10 response evaluable subjects (either IDHwt or IDHm Grade 4 astrocytoma) will be enrolled.
- Trial name
- NCT07431216
- Testing
- STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle., Spironolactone (drug)
- Volunteers
- 68 people
- Sponsor
- Starlight Therapeutics Inc.
Glioblastoma Multiforme
APG101 in Glioblastoma
This is a phase II study of APG101 + reirradiation (RT) versus reirradiation. Patients suffering from a malignant brain tumor called glioblastoma having a first or second progression can be included.
- Trial name
- NCT01071837
- Testing
- APG101, Blood drawing
- Where
- 21 sites in Austria, Germany
- Volunteers
- 84 people
- Sponsor
- Apogenix GmbH
Glioblastoma
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Open label phase I study in subjects with glioblastoma at first progression to explore two different administration schedules of lomustine for the combination with L19TNF (ARM 1 and ARM 2).
- Trial name
- GLIOASTRA (NCT05304663)
- Testing
- Onfekafusp alfa, Lomustine
- Sponsor
- Philogen S.p.A.
First Progression of MGMT Promoter-methylated Glioblastoma
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
Romiplostim for low platelets caused by lomustine chemotherapy in patients with first recurrence (growing back) of a brain tumor, glioblastoma that is MGMT methylated.
- Trial name
- RIGOLETTO (NCT04933942)
- Testing
- Lomustine, Romiplostim
- Where
- 5 sites in Spain, Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00516282
- Testing
- CLORETAZINE, temozolomide
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme
NOA-12: BIBF1120 and R-RT in Glioblastoma
Patients with glioblastoma at first or second progression who have failed standard treatment that must have included radiochemotherapy with temozolomide and who are a candidate for a reirradiation can be included into the trial.
- Trial name
- NCT01666600
- Testing
- BIBF 1120, radiotherapy
- Where
- 2 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Prof. Dr. Wolfgang Wick
Glioblastoma
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Glioblastomas are the most common and most aggressive primary brain tumors in adults. The prognosis is poor despite multimodal therapy with surgery, radiotherapy and chemotherapy. Therefore, novel treatments are urgently needed.
- Trial name
- GLIOSTAR (NCT04573192)
- Testing
- L19TNF, Lomustine
- Where
- 15 sites in France, Germany and 2 more
- Volunteers
- 142 people
- Sponsor
- Philogen S.p.A.
First Progression of Glioblastoma
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses.
- Trial name
- LEGATO (NCT05904119)
- Testing
- Lomustine, Reirradiation
- Where
- 45 sites in Austria, Belgium and 9 more
- Volunteers
- 411 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC